Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 72,05 € (+9,70 %). Medianen er 72,05 € (+9,70 %).

Køb
  18
Behold
  23
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Hologic taken private by Blackstone and TPG - stock valued at up to $79

    Blackstone and TPG funds have acquired Hologic and taken the company private at up to $79 per share. Shareholders will receive $76 in cash plus a non-tradable contingent value right that can enable up to $3 in additional payments in total if breast health revenue targets are met. Joe Almeida was appointed CEO, trading in the stock has been suspended and Hologic will be delisted from NASDAQ. Prior to the transaction, Hologic had a market capitalization of around $16.97 billion, annual revenue of $4.13 billion and a gross margin of 60%. » Mere på de.investing.com


  • Hologic reaches 52-week high at $76.01

    Hologic shares rose to a new 52‑week high of $76.01; market capitalization is $16.9 billion, year-to-date performance is +24.3% and the P/E ratio is about 31.45. Despite the share gain, Hologic missed expectations for the first fiscal quarter with revenue of $1.05 billion (consensus $1.07 billion) and adjusted EPS of $1.04 (consensus $1.09). CEO Steve MacMillan plans to retire after completion of the takeover approved by Blackstone and TPG. The Aptima HPV Assay received FDA approval for primary screening, expanding Hologic’s portfolio in cervical cancer early detection. » Mere på de.investing.com


  • Hologic: CEO Steve MacMillan to step down after takeover closes

    Steve MacMillan will relinquish his roles as chairman, president and CEO of Hologic once the takeover by Blackstone and TPG is expected to close around next Tuesday. During his more than 12-year tenure, revenue (+65%), adjusted earnings per share (+184%) and the share price (+241%) rose; market capitalization stands at USD 16.9 billion on annual revenue of USD 4.1 billion. The stock is trading near its 52-week high; a successor is expected to be announced at closing of the transaction. » Mere på de.investing.com


  • Hologic reaches 52-week high at $75.49

    Hologic shares closed at a new 52-week high of $75.49, rising 21.55% over the past 12 months. With a market capitalization of $16.85 billion and a P/E ratio of 31.39, the valuation sits at the higher end of the medical technology sector; InvestingPro currently views the stock as slightly undervalued with moderate upside potential. For the first fiscal quarter, Hologic reported revenue of $1.05 billion and adjusted earnings per share of $1.04, both missing analyst expectations. At the same time, Hologic’s Aptima HPV Assay received FDA approval for primary HPV screening with clinician-collected samples, becoming the only approved mRNA-based HPV test for detecting particularly cancer-relevant infections. » Mere på de.investing.com


  • Hologic hits 52-week high at $75.37

    Hologic shares rose to a new 52-week high of $75.37 and are up 16.84% over the past 12 months. An InvestingPro analysis views the stock as slightly undervalued with a fair value of $77.06, highlighting a gross profit margin of 60% and aggressive share buybacks. However, Hologic reported Q1 results that missed analyst estimates for both revenue ($1.05 billion) and adjusted EPS ($1.04). In addition, the Aptima HPV Assay received FDA approval for primary screening, giving Hologic three approved screening methods. » Mere på de.investing.com

I 2022 har Hologic allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Hologic en omsætning på 889,9 mio. € og et nettoresultat på 152,11 mio. €
(EUR) december 2025
YoY
Omsætning 889,9 mio. -
Bruttofortjeneste 498,03 mio. -
Nettoresultat 152,11 mio. -
EBITDA 277,64 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
15,48 mia. €
Antal aktier
223,24 mio.
Højeste/laveste i 52 uger
69,38 € - 47,33 €
Udbytte Nej
Beta
0,70
P/E (PE Ratio)
30,28
PEG (PEG Ratio)
-1,28
K/I (PB Ratio)
3,25
P/S (PS Ratio)
5,44

Virksomhedsprofil

Hologic, Inc. udvikler, fremstiller og leverer diagnostiske produkter, medicinske billeddannelsessystemer og kirurgiske produkter til kvinders sundhed gennem tidlig opdagelse og behandling i USA, Europa, Asien-Stillehavsområdet og internationalt. Virksomheden opererer gennem fire segmenter: Diagnostics, Breast Health, GYN Surgical og Skeletal Health. Selskabet leverer Aptima molekylære diagnostiske assays til påvisning af infektiøse mikroorganismer; Aptima viral load-tests til HIV, hepatitis C og hepatitis B; Aptima SARS-CoV-2- og Panther Fusion SARS-CoV-2-assays til påvisning af SARS-CoV-2; ThinPrep System til brug i cytologiske undersøgelser; Rapid Fetal Fibronectin Test, som hjælper læger med at vurdere risikoen for for tidlig fødsel; og forskellige diagnostiske tests til påvisning af Group B Streptococcus. Virksomheden tilbyder også billeddannelse og analyse af brystet, herunder 2D- og 3D-digitale mammografisystemer og arbejdsstationer til aflæsning, minimalt invasive vejledningssystemer og udstyr til brystbiopsi, markører og lokalisering af biopsisteder, specimenradiologi samt ultralyd- og konnektivitetsløsninger; og brystbevarende kirurgiske produkter. Derudover leverer selskabet NovaSure Endometrial Ablation System til behandling af unormal livmoderblødning; MyoSure Hysteroscopic Tissue Removal System til fjernelse af myomer, polypper og andre patologiske forandringer i livmoderen; og Fluent Fluid Management System, der giver væskedistention under diagnostiske og operative hysteroskopiske procedurer. Endvidere tilbyder selskabet Horizon DXA, et røntgensystem med dobbelt energi, og Fluoroscan Insight FD mini C-arm til at udføre minimalt invasive ortopædkirurgiske indgreb. Virksomheden sælger sine produkter gennem direkte salgs- og serviceorganisationer samt uafhængige distributører og salgsrepræsentanter. Hologic, Inc. blev stiftet i 1985 og har hovedkvarter i Marlborough, Massachusetts.

Navn
Hologic
CEO
Paul Malenchini
Hjemsted Marlborough, ma
USA
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
01.03.1990
Medarbejdere 7.063

Tickersymboler

Børs Symbol
NASDAQ
HOLX
London Stock Exchange
0J5Q.L
Frankfurt
HO1.F
Düsseldorf
HO1.DU
London
0J5Q.L
SIX
HO1.SW
München
HO1.MU
Wien
HOLX.VI
🍪

Parqet  bruger cookies. Læs mere